“The Tafenoquine for Babesiosis Expanded Access clinical study may strengthen that hope in a patient population that has few treatment options today. We are pleased to be leading the way in ...
60 Degrees Pharmaceuticals, Inc. announced the approval of an Investigational Review Board (IRB) for a Phase II clinical study aimed at evaluating the efficacy and safety of tafenoquine ...
“The promise shown by tafenoquine in treating relapsing babesiosis can certainly give patients and physicians reason for hope and optimism,” said Geoff Dow, PhD, chief executive officer of 60 ...
The National on MSN14d
Volunteers to be injected with malaria to study long-term effectsBritish scientists are infecting a group of volunteers with a type of malaria that can cause relapses years after contracting it to study its long-term effects. Plasmodium vivax is carried by ...
The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need. The clinical site is led by Brigham and Women’s Hospital ...
Physicians or patients who wish to participate in the 60 Degrees Pharmaceuticals Tafenoquine for Babesiosis Expanded Access clinical study are encouraged to visit the Company’s website for ...
A clinical case series recently published in Clinical Infectious Diseases showed that tafenoquine exhibited an 80 percent cure rate in five high-risk patients with persistent, relapsing babesiosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback